Agilent Technologies (NYSE:A) Updates Q3 2026 Earnings Guidance

Agilent Technologies (NYSE:A) issued an update on its third quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 1.480-1.500 for the period, compared to the consensus earnings per share estimate of 1.500. The company issued revenue guidance of $1.8 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion. Agilent Technologies also updated its FY 2026 guidance to 6.000-6.100 EPS.

Agilent Technologies Trading Up 17.2%

NYSE A opened at $135.79 on Friday. The company has a quick ratio of 1.59, a current ratio of 2.07 and a debt-to-equity ratio of 0.44. The firm has a market cap of $38.37 billion, a PE ratio of 27.27, a price-to-earnings-growth ratio of 2.44 and a beta of 1.22. The company has a 50 day moving average price of $115.45 and a 200 day moving average price of $128.71. Agilent Technologies has a 52 week low of $108.35 and a 52 week high of $160.27.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, May 27th. The medical research company reported $1.49 EPS for the quarter, topping the consensus estimate of $1.41 by $0.08. The firm had revenue of $1.84 billion during the quarter, compared to analyst estimates of $1.80 billion. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.74%. Agilent Technologies’s revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.31 EPS. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. As a group, sell-side analysts forecast that Agilent Technologies will post 5.95 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 22nd. Investors of record on Tuesday, June 30th will be paid a dividend of $0.255 per share. This represents a $1.02 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Tuesday, June 30th. Agilent Technologies’s payout ratio is 22.52%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Robert W. Baird upped their price target on shares of Agilent Technologies from $155.00 to $156.00 and gave the company an “outperform” rating in a research note on Tuesday. Wells Fargo & Company cut their price target on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research note on Thursday. TD Cowen upped their price target on shares of Agilent Technologies from $147.00 to $155.00 and gave the company a “buy” rating in a research note on Thursday. Bank of America upgraded shares of Agilent Technologies from a “neutral” rating to a “buy” rating and cut their price target for the company from $150.00 to $145.00 in a research note on Thursday. Finally, Wall Street Zen lowered shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $160.93.

More Agilent Technologies News

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported Q2 earnings of $1.49 per share, topping estimates, while revenue rose 10% year over year to about $1.83 billion, reinforcing the company’s momentum in lab tools and research equipment.
• Positive Sentiment: The company raised its full-year FY 2026 profit forecast and also guided Q3 and FY 2026 results above or in line with consensus, which suggests management sees continued demand strength ahead.
• Positive Sentiment: Bank of America upgraded Agilent to Buy from Neutral, citing improving demand and market share gains, while TD Cowen, Barclays, and RBC also issued favorable ratings and higher price targets.
• Positive Sentiment: Several market recaps highlighted Agilent as one of the standout post-earnings movers, with investors responding positively to the company’s execution, margin growth, and recurring revenue mix.
• Neutral Sentiment: One analyst note still described the stock as a hold despite the strong quarter, suggesting some investors may wait for more confirmation that the improved trend can persist. Agilent Technologies: A Solid Q2 Beat, But The Stock Remains A Hold
• Neutral Sentiment: An industry comparison article and a product announcement about OpenLab Sync were more informational than stock-moving, with limited immediate impact on the shares. Agilent Technologies (NYSE:A) vs. Lonza Group (OTCMKTS:LZAGY) Head-To-Head Comparison Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory

Institutional Trading of Agilent Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in A. AQR Capital Management LLC raised its holdings in shares of Agilent Technologies by 424.1% during the second quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock worth $240,956,000 after purchasing an additional 1,652,244 shares during the last quarter. Ameriprise Financial Inc. lifted its position in Agilent Technologies by 132.2% during the second quarter. Ameriprise Financial Inc. now owns 2,354,111 shares of the medical research company’s stock valued at $277,807,000 after purchasing an additional 1,340,161 shares during the period. Morgan Stanley lifted its position in Agilent Technologies by 15.9% during the fourth quarter. Morgan Stanley now owns 5,041,881 shares of the medical research company’s stock valued at $686,049,000 after purchasing an additional 692,202 shares during the period. Invesco Ltd. lifted its position in Agilent Technologies by 32.0% during the fourth quarter. Invesco Ltd. now owns 2,590,715 shares of the medical research company’s stock valued at $352,519,000 after purchasing an additional 627,804 shares during the period. Finally, Lazard Asset Management LLC lifted its position in Agilent Technologies by 639.4% during the second quarter. Lazard Asset Management LLC now owns 678,718 shares of the medical research company’s stock valued at $80,093,000 after purchasing an additional 586,931 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.